Video

Jeffrey Cohen, MD, Discusses New MS Criteria

Author(s):

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

The committee for the International Diagnostic Criteria for Multiple Sclerosis will be releasing its first update of multiple sclerosis (MS) diagnosing standards since 2010, later this year.

Jeffrey Cohen, MD, director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic, shared his inside-track knowledge of the machinations and discussions being had by the criteria-setters at the 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans this week.

Cohen sat down during CMSC to talk new criteria details, where issues lie in MS misdiagnosis, and how new forms of treatment could potentially influence diagnoses.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.